TabFH1

TabFH1 is a synthetic peptide inhibitor designed to target amyloid growth in transthyretin (TTR) amyloidosis. It is part of a series of peptides, with the "Tab" acronym referring to "transthyretin aggregation blockers." TabFH1 specifically targets one of the amyloid-driving segments of TTR, notably strand F, to inhibit aggregation and deposition of TTR fibrils. Its mechanism of action is based on capping pre-existing TTR fibrils, thereby halting further amyloid growth and seeding. However, TabFH1 displays only limited inhibitory activity compared to optimized second-generation inhibitors (such as TabFH2) and shows modest or no improvement in functional disease models. Research has demonstrated that, in animal models of familial amyloid polyneuropathy, TabFH1 has a limited capacity to reduce TTR deposition and no significant impact on disease-related locomotor decline. There is no evidence that TabFH1 is used in humans or has advanced to clinical development, and it is not associated with commercial developers or marketed formulations.